🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Korro is proud to be a Gold-Level Sponsor of the 2025 Harvard Rare Disease Hackathon on March 1-2. It brings together the next generation of scientists who share our passion for advancing solutions for rare diseases and will showcase their capabilities by solving challenges in

Korro CMO, Kemi Olugemo, MD, will be taking the stage at #RNALeaders Europe on Thursday, March 6, at 11:10 AM GMT+1 / 5:00 AM ET to present "Oligonucleotide Promoted Editing of RNA for Alpha-1 Antitrypsin Deficiency." Register to join us as we explore the potential of RNA

Korro Bio CEO & President, Ram Aiyar, will be presenting at the TD Cowen 45th Annual Health Care Conference on Tuesday, March 4, at 11:50 AM ET at the Boston Marriott Copley Place. Watch the live webcast here: ir.korrobio.com/events-present… $KRRO #TDCowenHealthCare

Today, on #RareDiseaseDay, we raise awareness for the 300 million people living with a rare disease. Korro had the privilege of hosting a special panel discussion featuring Dan Grimm, a patient living with Alpha-1 Antitrypsin Deficiency (#AATD). Dan shared his personal journey,

Our President & CEO, Ram Aiyar, joined Head of @NovoNordisk’s Bio Innovation Hub, Uli Stilz, on @BiotechTVHQ to discuss our groundbreaking #RNAEditing collaboration. Together, they explore how innovation thrives through partnerships between biotech pioneers and global leaders,

Breaking news! The U.S. FDA has granted orphan drug designation to KRRO-110 an investigational medicine for the treatment of Alpha-1 Antitrypsin Deficiency (#AATD). The designation underscores the FDA's recognition of the growing need for new treatments for patients living with

Today, we reported our full-year 2024 financial results and provided an update on recent progress and anticipated milestones. We are pleased to share that Korro has completed dosing of the first two cohorts in the Phase 1/2a REWRITE clinical study of KRRO-110 for alpha-1

Join us in welcoming Loïc Vincent, Ph.D., to the #KorroKrew as Chief Scientific Officer! With over 20 years of experience in drug discovery & translational research spanning academia, biotech, and pharma, Loïc has led teams to advance more than 20 drugs across various

Join us in welcoming Gaozhong Zhu, Ph.D., to the #KorroKrew as Senior Vice President of Chemistry, Manufacturing and Controls (CMC) & Technical Operations! With over 25 years of experience, Gaozhong has a proven track record of driving CMC strategies from concept to

Korro CMO, Kemi Olugemo, MD, is joining the community of 110+ biotech CMOs at the CMO Summit 360° in Boston. Dr. Olugemo will facilitate the CNS Roundtable discussion on Tuesday, April 8, from 1:05 - 1:50 PM ET. Learn more and register: cmosummit360.com #CMOSummit360

Todd Chappell, our Chief Operating Officer, will present at Jones Healthcare & Technology Innovation Conference on Wednesday, April 9, 11:30 AM ET / 2:30 PM PDT in Las Vegas. He will also participate in 1x1 investor meetings. To learn more about the conference agenda, visit

Today, Korro Bio reported its first quarter 2025 financial results and provided key business updates. Read the full release: ir.korrobio.com/news-releases/… $KRRO

Korro’s management will be participating in several upcoming investor conferences: - 2025 RBC Capital Markets Global Healthcare Conference - Jefferies Global Healthcare Conference - Goldman Sachs 46th Annual Global Healthcare Conference Watch the live RBC fireside chat on our “Events &

Our Associate Director, Tyson Moyer, Ph.D., will be presenting "Harnessing Endogenous ADAR for Oligo-Directed RNA Editing" at TIDES USA: Oligonucleotide & Peptide Therapeutics on Thursday, May 22, at 11:15 AM PT / 2:15 PM ET. Learn more: informaconnect.com/tides/speakers… TIDES - Informa Connect

Our President & CEO, Ram Aiyar, will take part in the panel discussion at #BIO2025. Among other panelists, he’ll be joined by Head of @NovoNordisk’s Bio Innovation Hub, Uli Stilz. - Cracking the Code: Effective Biotech and Pharma Partnerships Unveiled Tuesday, June 17 | 1:45 PM

Korro CMO, Kemi Olugemo, MD, will discuss advancements in rare disease drug development at a #BIO2025 panel, together with Nicole Verdun, MD, of the FDA, Nasha Fitter from Citizen Health / FOXG1 Research Foundation, and Sunitha Malepati from Buffalo Initiative / CACNA1A

At #BIO2025, our CMO, Kemi Olugemo, MD, and her fellow panelists Nasha Fitter and Sunitha Malepati discussed what a true partnership between patients and rare drug development companies looks like. It must include continuity of engagement, transparency, accessibility, and

A great panel of experts came together to discuss what makes biotech and pharma R&D partnerships truly work at #BIO2025: Korro President & CEO, Ram Aiyar, Uli Stilz, Head of @NovoNordisk’s Bio Innovation Hub, and Lovisa Afzelius, General Partner at Flagship Pioneering. A key